Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children

Pediatric Infectious Disease Journal

Volumn 22, Issue 3, 2003, Pages 216-223

  Sáez Llorens, Xavier ^a   Violari, Avyi ^b   Deetz, Carl O ^c   Rode, Richard A ^c   Gomez, Perry ^d   Handelsman, Edward ^e   Pelton, Stephen ^f   Ramilo, Octavio ^g   Cahn, Pedro ^h   Chadwick, Ellen ⁱ   Allen, Upton ^j   Arpadi, Stephen ^k   Castrejón, Maria Mercedes ^a   Heuser, Renee S ^c   Kempf, Dale J ^c   Bertz, Richard J ^c   Hsu, Ann F ^c   Bernstein, Barry ^c   Renz, Cheryl L ^c   Sun, Eugene ^c  

^a Hospital del Niño   (Panama)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c ABBOTT LABORATORIES   (United States)

^d Princess Margaret Hospital Nassau   (Bahamas)

^e University Hospital of Brooklyn   (United States)

^f Maxwell Finland Lab Infect Dis   (United States)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h FUNDACIÓN HUÉSPED   (Argentina)

ⁱ NORTHWESTERN UNIVERSITY   (United States)

^j HOSPITAL FOR SICK CHILDREN   (Canada)

^k ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

more..

Author keywords

Children; Human immunodeficiency virus infection; Lopinavir ritonavir; Protease inhibitor

Indexed keywords

CD4 ANTIGEN; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE;

ALLERGIC REACTION; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BODY SURFACE; CHILD; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MIXTURE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; FEMALE; FEVER; FISHER EXACT TEST; HEPATOMEGALY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PANCREATITIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; STATISTICAL MODEL; STEADY STATE; T LYMPHOCYTE SUBPOPULATION; TASTE DISORDER; VIRUS INFECTION; VIRUS ISOLATION; VIRUS LOAD; VIRUS REACTIVATION; VOMITING;

EID: 0037344230     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000055061.97567.34     Document Type: Article

References (14)

1. Nachman SA, Stanley K, Yogev R, et al. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children. JAMA 2000;283:492-8.
2. Krogstad P, Wiznia A, Luzuriaga K, et al. Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate. Clin Infect Dis 1999;28:1109-18.
3. Church J, Rathore M, Rubio T, et al. A Phase III study of amprenavir (APV, Agenerase) in protease-inhibitor naive and experienced HIV-infected children and adolescents [Abstract 693]. In: Program and abstracts of the Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, January 30 to February 2, 2000. Alexandria, VA: Foundation for Retrovirology and Human Health, 2000.
4. Blanche S, Fetter A, Cox H, et al. A Phase II study of amprenavir (APV, 141W94, AGENERASE) in antiretroviral-experienced children with HIV-infection [abstract 695]. In: Program and abstracts of the Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, January 30 to February 2, 2000. Alexandria, VA: Foundation for Retrovirology and Human Health, 2000.
5. Wiznia A, Stanley K, Krogstad P, et al. Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapyexperienced HIV-infected children: Week 24 results of a randomized controlled trial - PACTG 377. AIDS Res Hum Retroviruses 2000;16:1113-21.
6. Starr SE, Fletcher CV, Spector SA, et al. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. N Engl J Med 1999;341: 1874-81.
7. Kempf DJ. Discovery and early development of ritonavir and ABT-378. In: Ogden RC, Flexner CW, eds. Protease inhibitors in AIDS therapy. New York: Marcel Dekker, 2000:49-64.
8. Murphy RL, Brun S, Hicks C, et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS 2001;15:1-9.
9. Benson CA, Deeks SG, Brun SC, et al. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and two nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis 2002;185:599-607.
10. Petropoulos CJ, Parkin NT, Limoli KL, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000;44:920-8.
11. Molla A, Vasavanonda S, Kumar G, et al. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus. Virology 1998;250:255-62.
12. Hirsch MS, Brun-Vezinet F, D'Aquila RT, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA panel. JAMA 2000;283:2417-26.
13. Sande MA, Gilbert DN, Moellering RC, eds. The Sanford guide to HIV/AIDS therapy. 9th ed. Hyde Park, VT: Antimicrobial Therapy, 2000.
14. Kempf D, Bernstein B, King M, et al. Comparison of the emergence of genotypic resistance over 60 weeks of therapy with lopinavir/ritonavir (Kaletra) or nelfinavir plus d4T/3TC [Abstract 129]. In: Program and abstracts of the First IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina, July 8 to 11, 2001 (http://www.aids2001ias.org).